2Li X, Zheng J, Pan W, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study. Poster presented at: American Academy of Dermatology Virtual Meeting Experience; April 23-25, 2021.